Pacira BioSciences Enters Into Agreement With LG Chem To Expand Access To Opioid-Sparing Postsurgical Pain Control For Patients In Select Asian-Pacific Markets

Pacira Biosciences, Inc. -0.39%

Pacira Biosciences, Inc.

PCRX

22.70

-0.39%

-- LG Chem becomes exclusive distributor of EXPAREL -- 

– Partnership expands patient access to opioid-sparing pain control and advances 5x30 strategy–

BRISBANE, Calif., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced it has entered into an agreement with LG Chem designed to expand access to opioid-sparing postsurgical pain control for patients in select Asian-Pacific markets. Through this partnership, LG Chem has the exclusive rights to commercialize EXPAREL® (bupivacaine liposome injectable suspension), Pacira's long-acting, local analgesic for postsurgical pain management in the region.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.